Inventiva S.A. (IVA) 10-Year Financial Performance & Capital Metrics

IVA • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutInventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.Show more

Revenue $9M -47.4%
EBITDA -$92M +7.7%
Net Income -$184M -66.8%
EPS (Diluted) -3.54 -45.7%
Gross Margin 100% -0.1%
EBITDA Margin -1004.13% -75.3%
Operating Margin -1060.64% -80.5%
Net Margin -2002.74% -217.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -8.01 +59.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 14.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y10.85%

5Y5.62%

3Y29.92%

TTM15.39%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-205.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM-91.19%

ROCE

10Y Avg-164.67%

5Y Avg-289.23%

3Y Avg-454.76%

Latest-1106.16%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.87M	9.45M	6.52M	3.2M	7M	372K	4.19M	12.18M	17.48M	9.2M
Revenue Growth %	0.48%	0.94%	-0.31%	-0.51%	1.19%	-0.95%	10.27%	1.9%	0.44%	-0.47%
Cost of Goods Sold+	1.4M	1.49M	1.24M	967K	0	846K	0	995K	-23K	0
COGS % of Revenue	0.29%	0.16%	0.19%	0.3%	-	2.27%	-	0.08%	-0%	-
Gross Profit+	3.47M	7.96M	5.28M	2.23M	7M	4.42M	4.19M	17.06M	17.5M	9.2M
Gross Margin %	0.71%	0.84%	0.81%	0.7%	1%	11.87%	1%	1.4%	1%	1%
Gross Profit Growth %	0.97%	1.29%	-0.34%	-0.58%	2.14%	-0.37%	-0.05%	3.07%	0.03%	-0.47%
Operating Expenses+	19.75M	21.49M	26.99M	36.41M	36.21M	34.13M	56.31M	74.17M	120.19M	106.76M
OpEx % of Revenue	4.05%	2.28%	4.14%	11.39%	5.17%	91.76%	13.43%	6.09%	6.88%	11.61%
Selling, General & Admin	3.22M	3.3M	4.12M	4.52M	4.51M	9.06M	11.52M	15.49M	15.61M	17.1M
SG&A % of Revenue	0.66%	0.35%	0.63%	1.41%	0.65%	24.36%	2.75%	1.27%	0.89%	1.86%
Research & Development	19.64M	22.14M	26.73M	31.64M	33.79M	23.72M	48.45M	60.47M	110.01M	90.88M
R&D % of Revenue	4.03%	2.34%	4.1%	9.9%	4.83%	63.76%	11.55%	4.97%	6.29%	9.88%
Other Operating Expenses	0	0	0	257K	-2.09M	1.36M	-3.66M	-1.8M	-5.43M	-1.22M
Operating Income+	-15.51M	-13.02M	-20.92M	-33.25M	-30.31M	-29.72M	-52.11M	-57.11M	-102.71M	-97.56M
Operating Margin %	-3.18%	-1.38%	-3.21%	-10.4%	-4.33%	-79.89%	-12.43%	-4.69%	-5.88%	-10.61%
Operating Income Growth %	-0.15%	0.16%	-0.61%	-0.59%	0.09%	0.02%	-0.75%	-0.1%	-0.8%	0.05%
EBITDA+	-14.21M	-11.53M	-19.68M	-32.3M	-28.86M	-28.87M	-51.26M	-56.24M	-100.11M	-92.36M
EBITDA Margin %	-2.91%	-1.22%	-3.02%	-10.1%	-4.12%	-77.6%	-12.22%	-4.62%	-5.73%	-10.04%
EBITDA Growth %	-0.16%	0.19%	-0.71%	-0.64%	0.11%	-0%	-0.78%	-0.1%	-0.78%	0.08%
D&A (Non-Cash Add-back)	1.3M	1.49M	1.24M	949K	1.46M	849K	858K	870K	2.6M	5.2M
EBIT	-14.88M	-12.06M	-22.89M	-33.01M	-30.21M	-32.62M	-53.62M	-57.16M	-104.64M	-171.72M
Net Interest Income+	484.42K	488.66K	271K	-101.46K	138K	160K	-81K	-317K	-4.23M	-11.07M
Interest Income	227.63K	230.18K	276.62K	141.57K	157K	226K	57K	390K	945K	1.14M
Interest Expense	6.06K	7.55K	5.32K	243.03K	3K	66K	138K	707K	5.18M	12.18M
Other Income/Expense	486.14K	460.23K	278K	-111K	95K	-3.9M	2.84M	2.82M	-7.11M	-86.34M
Pretax Income+	-15.02M	-12.56M	-20.64M	-33.36M	-30.22M	-33.62M	-49.27M	-54.29M	-109.82M	-183.9M
Pretax Margin %	-3.08%	-1.33%	-3.16%	-10.44%	-4.32%	-90.37%	-11.75%	-4.46%	-6.28%	-19.99%
Income Tax+	-6.2M	-5.51M	-3.41M	253K	0	0	364K	-20K	607K	313K
Effective Tax Rate %	0.59%	0.56%	0.83%	1.01%	1%	1%	1.01%	1%	1.01%	1%
Net Income+	-8.82M	-7.05M	-17.23M	-33.62M	-30.22M	-33.62M	-49.64M	-54.27M	-110.43M	-184.21M
Net Margin %	-1.81%	-0.75%	-2.64%	-10.51%	-4.32%	-90.37%	-11.84%	-4.46%	-6.32%	-20.03%
Net Income Growth %	-0.18%	0.2%	-1.45%	-0.95%	0.1%	-0.11%	-0.48%	-0.09%	-1.03%	-0.67%
Net Income (Continuing)	-8.82M	-7.05M	-19.08M	-33.62M	-30.22M	-33.62M	-49.63M	-54.27M	-110.43M	-184.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.88	-0.45	-1.11	-1.64	-1.28	-0.99	-1.27	-1.31	-2.43	-3.54
EPS Growth %	-0.17%	0.49%	-1.47%	-0.48%	0.22%	0.23%	-0.28%	-0.03%	-0.85%	-0.46%
EPS (Basic)	-0.88	-0.45	-1.11	-1.64	-1.28	-0.99	-1.27	-1.31	-2.43	-3.54
Diluted Shares Outstanding	10.03M	15.74M	15.52M	20.54M	23.52M	33.87M	39.17M	41.45M	45.35M	51.98M
Basic Shares Outstanding	10.03M	15.68M	15.52M	20.54M	23.52M	33.87M	39.17M	41.45M	45.35M	51.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	28.61M	41.25M	67.22M	71.63M	48.88M	133M	115.58M	106.38M	48.19M	111.51M
Cash & Short-Term Investments	22.6M	24.87M	59.05M	56.69M	35.84M	113.02M	86.55M	87.78M	27.34M	96.56M
Cash Only	22.6M	24.87M	59.05M	56.69M	35.84M	105.69M	86.55M	86.74M	26.92M	96.56M
Short-Term Investments	0	0	0	0	0	7.34M	0	1.05M	70K	0
Accounts Receivable	986.72K	4.5M	6.86M	13.32M	643K	48K	11.59M	279K	15.71M	12.16M
Days Sales Outstanding	73.88	173.97	383.99	1.52K	33.54	47.1	1.01K	8.36	328.03	482.42
Inventory	480.44K	471.88K	473.13K	410K	387K	320K	392K	373K	417K	0
Days Inventory Outstanding	124.82	115.9	139.72	154.76	-	138.06	-	136.83	-6.62K	-
Other Current Assets	3.78M	13.55M	0	32K	11.51M	16.29M	9.59M	9.35M	69K	349K
Total Non-Current Assets+	31.96M	7.61M	7.15M	8.18M	8.08M	5.92M	6.41M	9.62M	21.37M	7.46M
Property, Plant & Equipment	5.57M	4.96M	4.52M	4.26M	3.72M	3.28M	3.2M	7.39M	9.13M	5M
Fixed Asset Turnover	0.87x	1.91x	1.44x	0.75x	1.88x	0.11x	1.31x	1.65x	1.91x	1.84x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	2.38M	2.07M	1.81M	1.54M	1.23M	935K	770K	568K	541K	48K
Long-Term Investments	23.48M	385.82K	238.62K	2.27M	2.33M	1.7M	1.75M	700K	1.43M	1.14M
Other Non-Current Assets	380.4K	0	333.33K	2.37M	3.13M	8K	-2K	968K	10.05M	1.05M
Total Assets+	60.58M	48.86M	74.37M	79.81M	56.96M	138.92M	121.98M	116M	69.56M	118.97M
Asset Turnover	0.08x	0.19x	0.09x	0.04x	0.12x	0.00x	0.03x	0.10x	0.25x	0.08x
Asset Growth %	-0.17%	-0.19%	0.52%	0.07%	-0.29%	1.44%	-0.12%	-0.05%	-0.4%	0.71%
Total Current Liabilities+	7.75M	8.6M	8.79M	15.08M	13.87M	13.91M	22.85M	30.7M	50.16M	120.73M
Accounts Payable	3.61M	4.36M	5.38M	8.37M	7.49M	6.92M	14.6M	19.36M	37.68M	32.86M
Days Payables Outstanding	938.03	1.07K	1.59K	3.16K	-	2.99K	-	7.1K	-597.95K	-
Short-Term Debt	194.01K	145.75K	307K	2.13M	77K	16K	1.24M	4.57M	3.01M	3.35M
Deferred Revenue (Current)	1000K	1000K	592.65K	548K	1000K	0	0	6K	6K	0
Other Current Liabilities	1.14M	1.09M	977K	1.89M	475K	5.56M	5.74M	2.28M	5.63M	73.4M
Current Ratio	3.69x	4.80x	7.64x	4.75x	3.53x	9.56x	5.06x	3.47x	0.96x	0.92x
Quick Ratio	3.63x	4.74x	7.59x	4.72x	3.50x	9.54x	5.04x	3.45x	0.95x	0.92x
Cash Conversion Cycle	-739.33	-782.09	-1.07K	-1.49K	-	-2.8K	-	-6.96K	591.66K	-
Total Non-Current Liabilities+	10.06M	4.54M	1.56M	3.13M	1.7M	13.8M	10.27M	39.83M	51.43M	104.88M
Long-Term Debt	503.99K	481.86K	220K	74K	0	10.04M	8.74M	25.43M	27.91M	46.33M
Capital Lease Obligations	-9.56M	0	0	0	2K	0	92K	3.23M	4.27M	2.13M
Deferred Tax Liabilities	9.08M	3.01M	-1.9M	9.3M	0	0	0	0	0	0
Other Non-Current Liabilities	0	944.42K	1.34M	1.39M	1.7M	3.76M	1.43M	11.11M	19.25M	56.31M
Total Liabilities	17.81M	13.14M	10.36M	18.22M	15.57M	27.71M	33.12M	70.53M	101.59M	225.61M
Total Debt+	698K	627.6K	482.07K	2.2M	114K	10.06M	10.12M	34.51M	37.49M	54.33M
Net Debt	-21.9M	-24.24M	-58.57M	-54.49M	-35.73M	-92.43M	-76.43M	-52.22M	10.57M	-42.23M
Debt / Equity	0.02x	0.02x	0.01x	0.04x	0.00x	0.09x	0.11x	0.76x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-2558.97x	-1724.82x	-3934.53x	-136.83x	-10104.00x	-450.27x	-377.64x	-80.78x	-19.84x	-8.01x
Total Equity+	42.77M	35.72M	64.01M	61.6M	41.39M	111.21M	88.87M	45.48M	-32.03M	-106.65M
Equity Growth %	-0.17%	-0.16%	0.79%	-0.04%	-0.33%	1.69%	-0.2%	-0.49%	-1.7%	-2.33%
Book Value per Share	4.26	2.27	4.13	3.00	1.76	3.28	2.27	1.10	-0.71	-2.05
Total Shareholders' Equity	42.77M	35.72M	64.01M	61.6M	41.39M	111.21M	88.87M	45.48M	-32.03M	-106.65M
Common Stock	100.3K	100.3K	164.44K	223K	268K	386K	409K	421K	521K	957K
Retained Earnings	-8.82M	-7.05M	-17.23M	-33.62M	-30.22M	-33.62M	-49.63M	-54.27M	-110.43M	-184.21M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	51.49M	42.67M	36.08M	17.53M	-14.67M	4.78M	-26.98M	-74.56M	-123.99M	-172.55M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.98M	-14.86M	-17M	-34.21M	-28.4M	-30.59M	-47.63M	-44.93M	-81.61M	-85.93M
Operating CF Margin %	-2.87%	-1.57%	-2.61%	-10.7%	-4.06%	-82.23%	-11.36%	-3.69%	-4.67%	-9.34%
Operating CF Growth %	0.05%	-0.06%	-0.14%	-1.01%	0.17%	-0.08%	-0.56%	0.06%	-0.82%	-0.05%
Net Income	-8.82M	-7.05M	-17.23M	-33.62M	-30.22M	-33.62M	-49.63M	-54.27M	-110.43M	-184.21M
Depreciation & Amortization	1.3M	1.65M	1.42M	2.32M	1.58M	1.89M	-1.29M	1.7M	2.6M	5.2M
Stock-Based Compensation	67.46K	3.1M	683.61K	833K	1.41M	938K	2.09M	2.22M	3.97M	3.58M
Deferred Taxes	-9.81M	-9.81M	-7.87M	-4.72M	-4.3M	-7.65M	-3.27M	-5.26M	-4.74M	-4.8M
Other Non-Cash Items	1.52M	-80.3K	3.45M	5K	3.89M	9.83M	3.5M	4.98M	9.68M	92.63M
Working Capital Changes	1.76M	-2.68M	2.55M	974K	-769K	-1.97M	979K	5.71M	17.31M	1.68M
Change in Receivables	-169.27K	-2.86M	1.82M	-3.09M	1.78M	-459K	-5.32M	3.84M	-5.84M	2.81M
Change in Inventory	-3.42K	8.56K	-1.25K	30K	22K	68K	-72K	19K	-44K	417K
Change in Payables	1.93M	924.63K	3.33M	4.82M	-2.97M	1.27M	7.6M	3.54M	20M	0
Cash from Investing+	18.85M	17.2M	6.17M	-420K	-826K	-8.56M	-1.79M	8.87M	-7.73M	8.74M
Capital Expenditures	-968.99K	-227.94K	-428.03K	-549K	-136K	-292K	-534K	-561K	-540K	-333K
CapEx % of Revenue	0.2%	0.02%	0.07%	0.17%	0.02%	0.78%	0.13%	0.05%	0.03%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-29.75K	-10.25K	631	23K	-690K	0	90K	1K	131K	0
Cash from Financing+	591.84K	-70.86K	45.01M	32.27M	8.38M	111.67M	25.45M	37.27M	29.08M	145.59M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	1K	1K	-130K	0	0	0	5.1M	68.33M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-14.95M	-15.09M	-17.43M	-34.76M	-28.54M	-30.88M	-48.16M	-45.49M	-82.15M	-86.26M
FCF Margin %	-3.07%	-1.6%	-2.67%	-10.87%	-4.08%	-83.02%	-11.48%	-3.74%	-4.7%	-9.38%
FCF Growth %	0.07%	-0.01%	-0.16%	-0.99%	0.18%	-0.08%	-0.56%	0.06%	-0.81%	-0.05%
FCF per Share	-1.49	-0.96	-1.12	-1.69	-1.21	-0.91	-1.23	-1.10	-1.81	-1.66
FCF Conversion (FCF/Net Income)	1.58x	2.11x	0.99x	1.02x	0.94x	0.91x	0.96x	0.83x	0.74x	0.47x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-18.72%	-17.95%	-34.55%	-53.53%	-58.69%	-44.06%	-49.62%	-80.8%	-1642.76%	-
Return on Invested Capital (ROIC)	-42.04%	-60.36%	-185.4%	-397.55%	-356%	-209.81%	-279.04%	-1506.6%	-	-
Gross Margin	71.18%	84.27%	81.05%	69.75%	100%	1187.37%	100%	140.05%	100.13%	100%
Net Margin	-181%	-74.59%	-264.22%	-1051.49%	-431.85%	-9037.37%	-1183.5%	-445.64%	-631.84%	-2002.74%
Debt / Equity	0.02x	0.02x	0.01x	0.04x	0.00x	0.09x	0.11x	0.76x	-	-
Interest Coverage	-2558.97x	-1724.82x	-3934.53x	-136.83x	-10104.00x	-450.27x	-377.64x	-80.78x	-19.84x	-8.01x
FCF Conversion	1.58x	2.11x	0.99x	1.02x	0.94x	0.91x	0.96x	0.83x	0.74x	0.47x
Revenue Growth	48.49%	93.77%	-30.96%	-50.97%	118.89%	-94.68%	1027.42%	190.39%	43.5%	-47.37%

Revenue by Geography

	2022	2023	2024
China	12.05M	4.61M	9.13M
China Growth	-	-61.76%	98.03%
France	125K	118K	69K
France Growth	-	-5.60%	-41.53%
JAPAN	-	12.75M	-
JAPAN Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Inventiva S.A. (IVA) reported $30.2M in revenue for fiscal year 2024. This represents a 885% increase from $3.1M in 2013.

Inventiva S.A. (IVA) saw revenue decline by 47.4% over the past year.

Inventiva S.A. (IVA) reported a net loss of $415.3M for fiscal year 2024.

Dividend & Returns

Inventiva S.A. (IVA) had negative free cash flow of $176.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Inventiva S.A. (IVA) 10-Year Financial Performance & Capital Metrics

IVA • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $9M -47.4%
EBITDA -$92M +7.7%
Net Income -$184M -66.8%
EPS (Diluted) -3.54 -45.7%
Gross Margin 100% -0.1%
EBITDA Margin -1004.13% -75.3%
Operating Margin -1060.64% -80.5%
Net Margin -2002.74% -217.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -8.01 +59.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 14.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y10.85%

5Y5.62%

3Y29.92%

TTM15.39%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-205.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM-91.19%

ROCE

10Y Avg-164.67%

5Y Avg-289.23%

3Y Avg-454.76%

Latest-1106.16%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.87M	9.45M	6.52M	3.2M	7M	372K	4.19M	12.18M	17.48M	9.2M
Revenue Growth %	0.48%	0.94%	-0.31%	-0.51%	1.19%	-0.95%	10.27%	1.9%	0.44%	-0.47%
Cost of Goods Sold+	1.4M	1.49M	1.24M	967K	0	846K	0	995K	-23K	0
COGS % of Revenue	0.29%	0.16%	0.19%	0.3%	-	2.27%	-	0.08%	-0%	-
Gross Profit+	3.47M	7.96M	5.28M	2.23M	7M	4.42M	4.19M	17.06M	17.5M	9.2M
Gross Margin %	0.71%	0.84%	0.81%	0.7%	1%	11.87%	1%	1.4%	1%	1%
Gross Profit Growth %	0.97%	1.29%	-0.34%	-0.58%	2.14%	-0.37%	-0.05%	3.07%	0.03%	-0.47%
Operating Expenses+	19.75M	21.49M	26.99M	36.41M	36.21M	34.13M	56.31M	74.17M	120.19M	106.76M
OpEx % of Revenue	4.05%	2.28%	4.14%	11.39%	5.17%	91.76%	13.43%	6.09%	6.88%	11.61%
Selling, General & Admin	3.22M	3.3M	4.12M	4.52M	4.51M	9.06M	11.52M	15.49M	15.61M	17.1M
SG&A % of Revenue	0.66%	0.35%	0.63%	1.41%	0.65%	24.36%	2.75%	1.27%	0.89%	1.86%
Research & Development	19.64M	22.14M	26.73M	31.64M	33.79M	23.72M	48.45M	60.47M	110.01M	90.88M
R&D % of Revenue	4.03%	2.34%	4.1%	9.9%	4.83%	63.76%	11.55%	4.97%	6.29%	9.88%
Other Operating Expenses	0	0	0	257K	-2.09M	1.36M	-3.66M	-1.8M	-5.43M	-1.22M
Operating Income+	-15.51M	-13.02M	-20.92M	-33.25M	-30.31M	-29.72M	-52.11M	-57.11M	-102.71M	-97.56M
Operating Margin %	-3.18%	-1.38%	-3.21%	-10.4%	-4.33%	-79.89%	-12.43%	-4.69%	-5.88%	-10.61%
Operating Income Growth %	-0.15%	0.16%	-0.61%	-0.59%	0.09%	0.02%	-0.75%	-0.1%	-0.8%	0.05%
EBITDA+	-14.21M	-11.53M	-19.68M	-32.3M	-28.86M	-28.87M	-51.26M	-56.24M	-100.11M	-92.36M
EBITDA Margin %	-2.91%	-1.22%	-3.02%	-10.1%	-4.12%	-77.6%	-12.22%	-4.62%	-5.73%	-10.04%
EBITDA Growth %	-0.16%	0.19%	-0.71%	-0.64%	0.11%	-0%	-0.78%	-0.1%	-0.78%	0.08%
D&A (Non-Cash Add-back)	1.3M	1.49M	1.24M	949K	1.46M	849K	858K	870K	2.6M	5.2M
EBIT	-14.88M	-12.06M	-22.89M	-33.01M	-30.21M	-32.62M	-53.62M	-57.16M	-104.64M	-171.72M
Net Interest Income+	484.42K	488.66K	271K	-101.46K	138K	160K	-81K	-317K	-4.23M	-11.07M
Interest Income	227.63K	230.18K	276.62K	141.57K	157K	226K	57K	390K	945K	1.14M
Interest Expense	6.06K	7.55K	5.32K	243.03K	3K	66K	138K	707K	5.18M	12.18M
Other Income/Expense	486.14K	460.23K	278K	-111K	95K	-3.9M	2.84M	2.82M	-7.11M	-86.34M
Pretax Income+	-15.02M	-12.56M	-20.64M	-33.36M	-30.22M	-33.62M	-49.27M	-54.29M	-109.82M	-183.9M
Pretax Margin %	-3.08%	-1.33%	-3.16%	-10.44%	-4.32%	-90.37%	-11.75%	-4.46%	-6.28%	-19.99%
Income Tax+	-6.2M	-5.51M	-3.41M	253K	0	0	364K	-20K	607K	313K
Effective Tax Rate %	0.59%	0.56%	0.83%	1.01%	1%	1%	1.01%	1%	1.01%	1%
Net Income+	-8.82M	-7.05M	-17.23M	-33.62M	-30.22M	-33.62M	-49.64M	-54.27M	-110.43M	-184.21M
Net Margin %	-1.81%	-0.75%	-2.64%	-10.51%	-4.32%	-90.37%	-11.84%	-4.46%	-6.32%	-20.03%
Net Income Growth %	-0.18%	0.2%	-1.45%	-0.95%	0.1%	-0.11%	-0.48%	-0.09%	-1.03%	-0.67%
Net Income (Continuing)	-8.82M	-7.05M	-19.08M	-33.62M	-30.22M	-33.62M	-49.63M	-54.27M	-110.43M	-184.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.88	-0.45	-1.11	-1.64	-1.28	-0.99	-1.27	-1.31	-2.43	-3.54
EPS Growth %	-0.17%	0.49%	-1.47%	-0.48%	0.22%	0.23%	-0.28%	-0.03%	-0.85%	-0.46%
EPS (Basic)	-0.88	-0.45	-1.11	-1.64	-1.28	-0.99	-1.27	-1.31	-2.43	-3.54
Diluted Shares Outstanding	10.03M	15.74M	15.52M	20.54M	23.52M	33.87M	39.17M	41.45M	45.35M	51.98M
Basic Shares Outstanding	10.03M	15.68M	15.52M	20.54M	23.52M	33.87M	39.17M	41.45M	45.35M	51.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	28.61M	41.25M	67.22M	71.63M	48.88M	133M	115.58M	106.38M	48.19M	111.51M
Cash & Short-Term Investments	22.6M	24.87M	59.05M	56.69M	35.84M	113.02M	86.55M	87.78M	27.34M	96.56M
Cash Only	22.6M	24.87M	59.05M	56.69M	35.84M	105.69M	86.55M	86.74M	26.92M	96.56M
Short-Term Investments	0	0	0	0	0	7.34M	0	1.05M	70K	0
Accounts Receivable	986.72K	4.5M	6.86M	13.32M	643K	48K	11.59M	279K	15.71M	12.16M
Days Sales Outstanding	73.88	173.97	383.99	1.52K	33.54	47.1	1.01K	8.36	328.03	482.42
Inventory	480.44K	471.88K	473.13K	410K	387K	320K	392K	373K	417K	0
Days Inventory Outstanding	124.82	115.9	139.72	154.76	-	138.06	-	136.83	-6.62K	-
Other Current Assets	3.78M	13.55M	0	32K	11.51M	16.29M	9.59M	9.35M	69K	349K
Total Non-Current Assets+	31.96M	7.61M	7.15M	8.18M	8.08M	5.92M	6.41M	9.62M	21.37M	7.46M
Property, Plant & Equipment	5.57M	4.96M	4.52M	4.26M	3.72M	3.28M	3.2M	7.39M	9.13M	5M
Fixed Asset Turnover	0.87x	1.91x	1.44x	0.75x	1.88x	0.11x	1.31x	1.65x	1.91x	1.84x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	2.38M	2.07M	1.81M	1.54M	1.23M	935K	770K	568K	541K	48K
Long-Term Investments	23.48M	385.82K	238.62K	2.27M	2.33M	1.7M	1.75M	700K	1.43M	1.14M
Other Non-Current Assets	380.4K	0	333.33K	2.37M	3.13M	8K	-2K	968K	10.05M	1.05M
Total Assets+	60.58M	48.86M	74.37M	79.81M	56.96M	138.92M	121.98M	116M	69.56M	118.97M
Asset Turnover	0.08x	0.19x	0.09x	0.04x	0.12x	0.00x	0.03x	0.10x	0.25x	0.08x
Asset Growth %	-0.17%	-0.19%	0.52%	0.07%	-0.29%	1.44%	-0.12%	-0.05%	-0.4%	0.71%
Total Current Liabilities+	7.75M	8.6M	8.79M	15.08M	13.87M	13.91M	22.85M	30.7M	50.16M	120.73M
Accounts Payable	3.61M	4.36M	5.38M	8.37M	7.49M	6.92M	14.6M	19.36M	37.68M	32.86M
Days Payables Outstanding	938.03	1.07K	1.59K	3.16K	-	2.99K	-	7.1K	-597.95K	-
Short-Term Debt	194.01K	145.75K	307K	2.13M	77K	16K	1.24M	4.57M	3.01M	3.35M
Deferred Revenue (Current)	1000K	1000K	592.65K	548K	1000K	0	0	6K	6K	0
Other Current Liabilities	1.14M	1.09M	977K	1.89M	475K	5.56M	5.74M	2.28M	5.63M	73.4M
Current Ratio	3.69x	4.80x	7.64x	4.75x	3.53x	9.56x	5.06x	3.47x	0.96x	0.92x
Quick Ratio	3.63x	4.74x	7.59x	4.72x	3.50x	9.54x	5.04x	3.45x	0.95x	0.92x
Cash Conversion Cycle	-739.33	-782.09	-1.07K	-1.49K	-	-2.8K	-	-6.96K	591.66K	-
Total Non-Current Liabilities+	10.06M	4.54M	1.56M	3.13M	1.7M	13.8M	10.27M	39.83M	51.43M	104.88M
Long-Term Debt	503.99K	481.86K	220K	74K	0	10.04M	8.74M	25.43M	27.91M	46.33M
Capital Lease Obligations	-9.56M	0	0	0	2K	0	92K	3.23M	4.27M	2.13M
Deferred Tax Liabilities	9.08M	3.01M	-1.9M	9.3M	0	0	0	0	0	0
Other Non-Current Liabilities	0	944.42K	1.34M	1.39M	1.7M	3.76M	1.43M	11.11M	19.25M	56.31M
Total Liabilities	17.81M	13.14M	10.36M	18.22M	15.57M	27.71M	33.12M	70.53M	101.59M	225.61M
Total Debt+	698K	627.6K	482.07K	2.2M	114K	10.06M	10.12M	34.51M	37.49M	54.33M
Net Debt	-21.9M	-24.24M	-58.57M	-54.49M	-35.73M	-92.43M	-76.43M	-52.22M	10.57M	-42.23M
Debt / Equity	0.02x	0.02x	0.01x	0.04x	0.00x	0.09x	0.11x	0.76x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-2558.97x	-1724.82x	-3934.53x	-136.83x	-10104.00x	-450.27x	-377.64x	-80.78x	-19.84x	-8.01x
Total Equity+	42.77M	35.72M	64.01M	61.6M	41.39M	111.21M	88.87M	45.48M	-32.03M	-106.65M
Equity Growth %	-0.17%	-0.16%	0.79%	-0.04%	-0.33%	1.69%	-0.2%	-0.49%	-1.7%	-2.33%
Book Value per Share	4.26	2.27	4.13	3.00	1.76	3.28	2.27	1.10	-0.71	-2.05
Total Shareholders' Equity	42.77M	35.72M	64.01M	61.6M	41.39M	111.21M	88.87M	45.48M	-32.03M	-106.65M
Common Stock	100.3K	100.3K	164.44K	223K	268K	386K	409K	421K	521K	957K
Retained Earnings	-8.82M	-7.05M	-17.23M	-33.62M	-30.22M	-33.62M	-49.63M	-54.27M	-110.43M	-184.21M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	51.49M	42.67M	36.08M	17.53M	-14.67M	4.78M	-26.98M	-74.56M	-123.99M	-172.55M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.98M	-14.86M	-17M	-34.21M	-28.4M	-30.59M	-47.63M	-44.93M	-81.61M	-85.93M
Operating CF Margin %	-2.87%	-1.57%	-2.61%	-10.7%	-4.06%	-82.23%	-11.36%	-3.69%	-4.67%	-9.34%
Operating CF Growth %	0.05%	-0.06%	-0.14%	-1.01%	0.17%	-0.08%	-0.56%	0.06%	-0.82%	-0.05%
Net Income	-8.82M	-7.05M	-17.23M	-33.62M	-30.22M	-33.62M	-49.63M	-54.27M	-110.43M	-184.21M
Depreciation & Amortization	1.3M	1.65M	1.42M	2.32M	1.58M	1.89M	-1.29M	1.7M	2.6M	5.2M
Stock-Based Compensation	67.46K	3.1M	683.61K	833K	1.41M	938K	2.09M	2.22M	3.97M	3.58M
Deferred Taxes	-9.81M	-9.81M	-7.87M	-4.72M	-4.3M	-7.65M	-3.27M	-5.26M	-4.74M	-4.8M
Other Non-Cash Items	1.52M	-80.3K	3.45M	5K	3.89M	9.83M	3.5M	4.98M	9.68M	92.63M
Working Capital Changes	1.76M	-2.68M	2.55M	974K	-769K	-1.97M	979K	5.71M	17.31M	1.68M
Change in Receivables	-169.27K	-2.86M	1.82M	-3.09M	1.78M	-459K	-5.32M	3.84M	-5.84M	2.81M
Change in Inventory	-3.42K	8.56K	-1.25K	30K	22K	68K	-72K	19K	-44K	417K
Change in Payables	1.93M	924.63K	3.33M	4.82M	-2.97M	1.27M	7.6M	3.54M	20M	0
Cash from Investing+	18.85M	17.2M	6.17M	-420K	-826K	-8.56M	-1.79M	8.87M	-7.73M	8.74M
Capital Expenditures	-968.99K	-227.94K	-428.03K	-549K	-136K	-292K	-534K	-561K	-540K	-333K
CapEx % of Revenue	0.2%	0.02%	0.07%	0.17%	0.02%	0.78%	0.13%	0.05%	0.03%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-29.75K	-10.25K	631	23K	-690K	0	90K	1K	131K	0
Cash from Financing+	591.84K	-70.86K	45.01M	32.27M	8.38M	111.67M	25.45M	37.27M	29.08M	145.59M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	1K	1K	-130K	0	0	0	5.1M	68.33M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-14.95M	-15.09M	-17.43M	-34.76M	-28.54M	-30.88M	-48.16M	-45.49M	-82.15M	-86.26M
FCF Margin %	-3.07%	-1.6%	-2.67%	-10.87%	-4.08%	-83.02%	-11.48%	-3.74%	-4.7%	-9.38%
FCF Growth %	0.07%	-0.01%	-0.16%	-0.99%	0.18%	-0.08%	-0.56%	0.06%	-0.81%	-0.05%
FCF per Share	-1.49	-0.96	-1.12	-1.69	-1.21	-0.91	-1.23	-1.10	-1.81	-1.66
FCF Conversion (FCF/Net Income)	1.58x	2.11x	0.99x	1.02x	0.94x	0.91x	0.96x	0.83x	0.74x	0.47x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-18.72%	-17.95%	-34.55%	-53.53%	-58.69%	-44.06%	-49.62%	-80.8%	-1642.76%	-
Return on Invested Capital (ROIC)	-42.04%	-60.36%	-185.4%	-397.55%	-356%	-209.81%	-279.04%	-1506.6%	-	-
Gross Margin	71.18%	84.27%	81.05%	69.75%	100%	1187.37%	100%	140.05%	100.13%	100%
Net Margin	-181%	-74.59%	-264.22%	-1051.49%	-431.85%	-9037.37%	-1183.5%	-445.64%	-631.84%	-2002.74%
Debt / Equity	0.02x	0.02x	0.01x	0.04x	0.00x	0.09x	0.11x	0.76x	-	-
Interest Coverage	-2558.97x	-1724.82x	-3934.53x	-136.83x	-10104.00x	-450.27x	-377.64x	-80.78x	-19.84x	-8.01x
FCF Conversion	1.58x	2.11x	0.99x	1.02x	0.94x	0.91x	0.96x	0.83x	0.74x	0.47x
Revenue Growth	48.49%	93.77%	-30.96%	-50.97%	118.89%	-94.68%	1027.42%	190.39%	43.5%	-47.37%

Revenue by Geography

	2022	2023	2024
China	12.05M	4.61M	9.13M
China Growth	-	-61.76%	98.03%
France	125K	118K	69K
France Growth	-	-5.60%	-41.53%
JAPAN	-	12.75M	-
JAPAN Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Inventiva S.A. (IVA) reported $30.2M in revenue for fiscal year 2024. This represents a 885% increase from $3.1M in 2013.

Inventiva S.A. (IVA) saw revenue decline by 47.4% over the past year.

Inventiva S.A. (IVA) reported a net loss of $415.3M for fiscal year 2024.

Dividend & Returns

Inventiva S.A. (IVA) had negative free cash flow of $176.9M in fiscal year 2024, likely due to heavy capital investments.